Spondyloarthritis & psoriatic arthritis
Evolution of gut microbiota in psoriatic arthritis treated with IL-17 inhibitor revealed by metagenomics
Authors' conclusion
Treatment with IL-17i induces gut microbiota evolution in PsA patients. The key features of this evolution include increased α-diversity, expansion of the Phocaeicola genus, and upregulation of CAZymes.
Study context
- Population
- PsA patients treated with secukizumab (IL-17i)60 fecal samples
- Participants
- 20 patients
- Exposure
- Gut microbiota at 1 and 3 months of secukinumab vs before treatment
- Outcome
- Evolution of gut microbiota in taxonomy and function
Methodological detailslongitudinal, shotgun metagenomic sequencing
- Longitudinal
- Shotgun metagenomic sequencing
Main finding
As reported in the abstract
- Bacteroidota phylum expanded; Phocaeicola genus abundance increased gradually with treatment time
- P<0.05
Observational data: associations, not effects.
Further findings
Disease activity · 1 mo. and 3 mo.
- Disease activity decreased significantly
Original publication
Evolution of gut microbiota in psoriatic arthritis treated with IL-17 inhibitor revealed by metagenomics. Joint Bone Spine. Published 25 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →